content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <!-- Field: Pseudo-Tag; ID: Name; Data: ORBIMED ADVISORS LLC -->
            <cik>0001055951</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001672619</issuerCik>
        <issuerName>Enliven Therapeutics, Inc.</issuerName>
        <secFileNumber>001-39247</secFileNumber>
        <issuerAddress>
          <com:street1>6200 Lookout Road</com:street1>
          <com:city>Boulder</com:city>
          <com:stateOrCountry>CO</com:stateOrCountry>
          <com:zipCode>80301</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>720-647-8519</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Genesis Master Fund, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Director</relationshipToIssuer>
          <relationshipToIssuer>Shareholder</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Morgan Stanley &amp; Co. LLC</name>
          <address>
            <com:street1>1585 Broadway</com:street1>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10036</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>33300</noOfUnitsSold>
        <aggregateMarketValue>737262.00</aggregateMarketValue>
        <noOfUnitsOutstanding>47036698</noOfUnitsOutstanding>
        <approxSaleDate>05/16/2024</approxSaleDate>
        <securitiesExchangeName>Nasdaq</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <acquiredDate>02/23/2023</acquiredDate>
        <natureOfAcquisitionTransaction>Merger</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>33300</amountOfSecuritiesAcquired>
        <paymentDate>02/23/2023</paymentDate>
        <natureOfPayment>N/A</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <remarks>OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P. OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC.</remarks>
      <noticeSignature>
        <noticeDate>05/17/2024</noticeDate>
        <signature>/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Genesis Master Fund, L.P.</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 3163}]
text: 144
  0001055951
  XXXXXXXX
  LIVE
  0001672619
  Enliven Therapeutics, Inc.
  001-39247
  6200 Lookout Road
  Boulder
  CO
  80301
  720-647-8519
  OrbiMed Genesis Master Fund, L.P.
  Director
  Shareholder
  Common Stock
  Morgan Stanley & Co. LLC
  1585 Broadway
  New York
  NY
  10036
  33300
  737262.00
  47036698
  05/16/2024
  Nasdaq
  Common Stock
  02/23/2023
  Merger
  Issuer
  N
  33300
  02/23/2023
  N/A
  Y
  OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P. OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC.
  05/17/2024
  /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Genesis Master Fund, L.P.